Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054515 | 1.00 | PIK3R1 (0.44) | PIK3R1PIK3CAMEN1ALDH1A1MAPT | |
| SCHEMBL4060638 | 0.91 | PIK3R1 (0.44) | PIK3R1PIK3CAMEN1ALDH1A1MAPT | |
| SCHEMBL4060633 | 0.91 | PIK3R1 (0.44) | PIK3R1PIK3CAMEN1ALDH1A1MAPT | |
| SCHEMBL4053726 | 0.86 | UTRN (0.47) | PIK3R1PIK3CAMEN1ALDH1A1RAB9A | |
| SCHEMBL4053724 | 0.86 | UTRN (0.47) | PIK3R1PIK3CAMEN1ALDH1A1RAB9A | |
| SCHEMBL4051094 | 0.84 | ERBB2 (0.52) | MEN1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL4051101 | 0.84 | ERBB2 (0.52) | MEN1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL4062204 | 0.78 | PIK3R1 (0.44) | PIK3R1PIK3CAMEN1ALDH1A1MAPT | |
| SCHEMBL4062200 | 0.78 | PIK3R1 (0.44) | PIK3R1PIK3CAMEN1ALDH1A1MAPT | |
| SCHEMBL4055549 | 0.77 | ERBB2 (0.46) | MEN1ALDH1A1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | PIK3R1 565/4885PIK3CA 848/4885MEN1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.